CompanyDrug

Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment

Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer's Disease Initiation
CompanyDrug

Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer’s Disease Initiation

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market
CompanyDeals

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients
CompanyDeals

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients

Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

CompanyDeals

Hisun Pharmaceutical Secures Exclusive Rights to TISA-818 – Novel Multi-Target Immunomodulator for ARDS and Pulmonary Fibrosis

Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

China's NMPA Suspends Medochemie's Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure
Policy / Regulatory

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

CompanyDrug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

CompanyDeals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

CompanyDrug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

CompanyDrug

Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody